The company is focusing its research initiatives in advanced wound healing technologies in the area of Prolonged Field Care and Regenerative Medicine with the continued support of the US Department of Defense, the US Army, the Defense Health Agency and the SBIR. Applied Tissue’s initiatives include the development and commercialization of a multi-modal negative pressure wound therapy platform technology that eliminates foam or gauze wound contact layer required in currently available competing devices.
We believe that this technology called the Platform Wound Device “PWD” will have a major impact in treating traumatic injuries and burns in the war fighter and may provide answers to some of the challenges presented with the currently available NPWT technology. The PWD’s properties will also enable, fast, wide-spread deployment during a large scale civilian casualty event, as well as support the daily treatment of common acute and chronic wounds. The technology will support immediate delivery of topical therapeutics to include analgesia, antimicrobial and other liquid, gel or ointment formulations.